Sponsor & Developer Portfolio
Tor Biering-Sørensen
Clinical development pipeline, platform architecture, and registered trial tracking for Tor Biering-Sørensen vaccine candidates.
2
Candidates
2
Target Diseases
2
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 2
Platform Technologies
mRNA: 1 Protein / subunit: 1
Target Pathogens & Indications
COVID-19 Varicella / Zoster
Vaccine Pipeline Candidates (2)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 3 Clinical Trial
ctgov-recombinant-herpes-zoster-vaccine-shingrix-tor-biering-s-rensen
Recombinant Herpes Zoster Vaccine (Shingrix)
Target: Varicella / Zoster
Platform: Protein / subunit
Key Milestone: Primary completion (most advanced trial): 2029-04 (registry estimate)
Phase 3 Clinical Trial
ctgov-mrna-1273-moderna-covid-19-vaccine-tor-biering-s-rensen
mRNA-1273 (Moderna COVID-19 vaccine)
Target: COVID-19
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2026-08 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.